Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • GI 254023X: Selective ADAM10 Metalloprotease Inhibitor fo...

    2026-01-23

    GI 254023X: Selective ADAM10 Metalloprotease Inhibitor for Acute Leukemia and Vascular Models

    Executive Summary: GI 254023X is a potent, selective inhibitor of the ADAM10 metalloprotease, exhibiting an IC50 of 5.3 nM and >100-fold selectivity over ADAM17 under in vitro assay conditions (APExBIO). It blocks ADAM10-mediated cleavage events, including fractalkine (CX3CL1) and Notch1, which are central to cell signaling and adhesion. GI 254023X induces apoptosis in Jurkat T-lymphoblastic leukemia cells and prevents VE-cadherin cleavage in human pulmonary artery endothelial cells (HPAECs), protecting against Staphylococcus aureus α-hemolysin–mediated barrier disruption. In vivo, daily intraperitoneal administration at 200 mg/kg confers vascular protection in BALB/c mice. The compound is insoluble in water but dissolves at ≥42.6 mg/mL in DMSO and ≥46.1 mg/mL in ethanol, supporting robust experimental integration (Satir et al., 2020).

    Biological Rationale

    ADAM10 (A Disintegrin and Metalloproteinase 10, EC 3.4.24.81) is a membrane-anchored protease involved in the shedding of various cell surface proteins. Its substrates include Notch1, fractalkine (CX3CL1), and VE-cadherin, all implicated in cell–cell communication, immune modulation, and endothelial barrier function (Satir et al., 2020). Aberrant ADAM10 activity is associated with oncogenesis, neurodegeneration, and vascular leakage. Selective ADAM10 inhibition enables targeted modulation of these pathways, minimizing off-target effects linked to broader-spectrum metalloprotease inhibitors. In acute T-lymphoblastic leukemia and vascular injury models, ADAM10 inhibition offers a mechanistically precise tool for dissecting cell signaling and survival pathways (Related article; this article extends the discussion by emphasizing validated in vivo benchmarks and solubility parameters.).

    Mechanism of Action of GI 254023X

    GI 254023X is a small-molecule inhibitor with a molecular weight of 391.5 Da and formula C21H33N3O4 (GI 254023X product page). It binds to the active site of ADAM10, blocking metalloprotease-mediated peptide hydrolysis. The compound demonstrates an IC50 of 5.3 nM for ADAM10, with >100-fold selectivity over ADAM17 in fluorometric peptide cleavage assays at neutral pH and 37°C. By inhibiting ADAM10, GI 254023X prevents constitutive and induced cleavage of substrates such as fractalkine, Notch1, and VE-cadherin, thereby modulating downstream signaling cascades (e.g., Notch1/Hes-1 transcriptional axis). Its selectivity profile enables discrimination between ADAM10- and ADAM17-dependent pathways, supporting mechanistic studies in oncology and vascular biology (Related article; this article clarifies in vivo dosing and solubility integration.).

    Evidence & Benchmarks

    • GI 254023X inhibits ADAM10 activity with an IC50 of 5.3 nM in cell-free biochemical assays (APExBIO, product page).
    • Demonstrates >100-fold selectivity for ADAM10 over ADAM17 under identical assay conditions (internal source).
    • Blocks constitutive fractalkine (CX3CL1) cleavage in cellular models (37°C, 5% CO2, 24 h exposure) (Satir et al., 2020).
    • Inhibits proliferation and induces apoptosis in Jurkat T-lymphoblastic leukemia cells, modulating Notch1, cleaved Notch1, MCL-1, and Hes-1 mRNA (qPCR, 24–48 h) (internal source).
    • Prevents VE-cadherin cleavage and protects against Staphylococcus aureus α-hemolysin–mediated endothelial barrier disruption in HPAECs (in vitro, 37°C, 2–6 h post-toxin exposure) (internal source).
    • In vivo, intraperitoneal administration of GI 254023X at 200 mg/kg/day for 3 days enhances vascular integrity and prolongs survival in BALB/c mice challenged with bacterial toxins (APExBIO, product page).
    • GI 254023X is insoluble in water but dissolves at ≥42.6 mg/mL in DMSO and ≥46.1 mg/mL in ethanol; recommended storage is at –20°C (APExBIO, product page).

    Applications, Limits & Misconceptions

    GI 254023X serves as a reference inhibitor for dissecting ADAM10-specific functions in cell signaling, apoptosis, and vascular permeability. It is validated for use in:

    • Acute T-lymphoblastic leukemia cell models for apoptosis and gene expression studies.
    • Endothelial barrier disruption assays, including Staphylococcus aureus α-hemolysin challenge.
    • In vivo vascular integrity models in rodents.
    • Notch1 signaling pathway interrogation in oncology and developmental biology.

    This article extends previous scenario-based solutions by providing structured evidence on in vivo performance and detailed physicochemical integration guidelines.

    Common Pitfalls or Misconceptions

    • GI 254023X is not suitable for applications requiring ADAM17 inhibition; its selectivity profile precludes robust ADAM17 targeting.
    • The compound is insoluble in aqueous buffers; dissolution in DMSO or ethanol is essential for reliable experimental delivery.
    • Stock solutions stored at –20°C are stable short-term, but repeated freeze–thaw cycles or prolonged storage of dissolved material may lead to degradation.
    • GI 254023X is for research use only and is not approved for diagnostic or therapeutic use in humans or animals.
    • It does not inhibit β-secretase (BACE1); thus, it cannot be used as a BACE1 inhibitor in Alzheimer’s disease models (Satir et al., 2020).

    Workflow Integration & Parameters

    GI 254023X is supplied as a white solid by APExBIO (A4436 kit). Reconstitute at ≥42.6 mg/mL in DMSO or ≥46.1 mg/mL in ethanol, using warming (37°C) and sonication if needed. Working concentrations in cellular assays typically range from 1–1000 nM, adjusted for cell type and application. For in vivo studies in mice, intraperitoneal injection of 200 mg/kg/day for 3 days has documented efficacy for vascular protection. Avoid long-term storage of solutions; prepare fresh aliquots when possible. GI 254023X is suitable for robust, reproducible workflows in cell signaling, apoptosis, and vascular integrity models (Related: this article provides additional guidance on cell signaling endpoints.).

    Conclusion & Outlook

    GI 254023X is a validated, highly selective ADAM10 inhibitor with proven efficacy in cellular and in vivo models. Its robust selectivity, well-defined solubility, and reproducible performance make it a superior tool for acute T-lymphoblastic leukemia, vascular disruption, and signaling pathway research. As the landscape of metalloprotease inhibition evolves, GI 254023X, distributed by APExBIO, stands out as a benchmark reference for high-specificity ADAM10 targeting. Future clinical translation will require confirmation of safety and efficacy in advanced models. For further reading on ADAM10-targeted workflows, see Precision Targeting of ADAM10 (this article updates with additional in vivo and solubility data).